NBI-827104

· Neurocrine Biosciences

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for NBI-827104, covering 2022-07-12 to 2026-02-13. Get the full timeline:

Most recent: Clinical Trial Update: Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep [Phase 2]

See pricing